Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome

Journal of Autoimmunity

Volumn 15, Issue 2, 2000, Pages 237-240

  Meroni, P L ^a   Raschi, E ^b   Camera, M ^b   Testoni, C ^a   Nicoletti, F ^c   Tincani, A ^d   Khamashta, M A ^e   Balestrieri, G ^d   Tremoli, E ^b   Hess, D C ^c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Servizio Immunologia Clinica   (Italy)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti 2 glycoprotein I antibodies; Atherosclerosis; Endothelial cells; Statins

Indexed keywords

BETA2 GLYCOPROTEIN 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; PHOSPHOLIPID ANTIBODY;

ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CELL ACTIVATION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FETUS WASTAGE; HUMAN; HYPERCHOLESTEROLEMIA; PATHOGENESIS; PRIORITY JOURNAL; THROMBOSIS;

EID: 0033826480     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0412     Document Type: Conference Paper

References (41)

1. Immunology of the antiphospholipid antibody syndrome
2. Beta2-glycoprotein
3. Beta2-glycoprotein I as a 'co-factor' for anti-phospholipid reactivity with endothelial cells
4. Antiphospholipid antibodies affect trophoblast gonadotrophin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I
5. Immune recognition at the maternal-fetal interface: Overview
6. β2-Glycoprotein I and placental anti-coagulant protein I in placentae from patients with antiphospholipid syndrome
7. Relationship between anti-phospholipid and anti-endothelial antibodies III: β2-Glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules
8. Role of β2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells
9. Activation of cultured vascular endothelial cells by antiphospholipid antibodies
10. Endothelial cell as target for antiphospholipid antibodies
11. Differential effects of anti-beta 2 glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome
12. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2glycoprotein I antibodies
13. Human β2-GPI binds to trophoblast through its fifth domain affecting human chorionic gonadotrophin release. Abstract submitted to the 9th International Symposium on Antiphospholipid Antibodies
14. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
15. Antigenic heterogeneity of vascular endothelium
16. Vascular-Bed Specific hemostasis and hypercoagulable states
17. aPL Reactivity with human brain microvascular endothelial cells (BEC)
18. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage
19. Increased soluble vascular adhesion molecule 1 concentrations in patients with primary or systemic lupus-erythematosus syndrome: Correlations with the severity of thrombosis
20. The anti-phospholipid (Hughes) syndrome: A crossroads of autoimmunity and atherosclerosis
21. Atherosclerosis in SLE and Hughes syndrome
22. Molecular basis of the acute coronary syndromes
23. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
24. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
25. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors
26. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
27. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
28. Vastatin inhibit cholesterol ester accumulation in human monocyte-derived macrophages
29. HMGCoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages
30. Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products
31. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells
32. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
33. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
34. Vastatin inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis
35. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
36. Endothelial cells in physiology and in the pathophysiology of vascular disorders
37. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitrix oxide synthase in vascular endothelial cells
38. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
39. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
40. Antiendothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro
41. Murine models of systemic lupus erythematosus